Shenlian Biotech

Shenlian Biotech is a prominent Chinese biotechnology company dedicated to the development and commercialization of veterinary vaccines and diagnostic reagents. The company achieved global recognition by launching the first synthetic peptide vaccine for Foot-and-Mouth Disease (FMD), establishing itself as a leader in the animal health sector. Its core business revolves around a sophisticated synthetic peptide technology platform that allows for the precise design of antigens to combat livestock diseases. Shenlian Biotech operates large-scale manufacturing bases in Shanghai and Lanzhou, ensuring high-quality production standards for its commercial portfolio. Publicly traded on the Shanghai Stock Exchange, the company continues to expand its pipeline into other significant swine and bovine indications.